Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01510158 · ClinicalTrials.gov registry record · Phase 3
Combining Lesinurad With Allopurinol in Inadequate Responders
A Phase 3 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 607
- Enrollment target
NCT01510158 is a Phase 3 study that has completed, run by Ardea Biosciences. The registered enrollment target is 607 participants.
The verdict
NCT01510158, a Phase 3 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 607 participants
- Enrollment target
Study Summary
This study that compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to allopurinol.
Interventions
- DRUG Placebo
- DRUG Allopurinol
- DRUG Lesinurad
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 607 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01510158
The ClinicalTrials.gov registry entry for NCT01510158 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 607 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01510158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01510158 about?
NCT01510158 is a clinical study titled "Combining Lesinurad With Allopurinol in Inadequate Responders". This study that compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to allopurinol.
What is the current status of trial NCT01510158?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 607 participants. The study started on 2012-01. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01510158?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), Lesinurad (DRUG).
Who is sponsoring clinical trial NCT01510158?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.